Investors
Presentation of Q4 2022 report
CEO Pia Renaudin presented the fourth quarter 2022 report on February 1, 14:00 CET.
Extraordinary General Meeting, February 16
Neuromuscular blockade management guidelines
New guidelines recommend Senzime's type of technology
Latest guidelines from both ESAIC European Society of Anaesthesiology and Intensive Care and American Society of Anesthesiologists (ASA) strongly recommend the use of quantitative monitoring neuromuscular blockade.
TetraGraph is a quantitative neuromuscular monitor, based on state-of-the-art EMG technology, enabling you as a clinican to make confident decisions from start to finish of a procedure.
A Swedish medical device company
Senzime develops, manufactures and markets CE- and FDA-cleared patient monitoring systems.
Our vision is a world without anesthesia and respiratory-related complications.
CEO Statement
High growth in the USA driven by new business customers and increased use of disposables
Pia Renaudin, CEO
November 2022